SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM BIPHASIC HUMAN INSULIN 30 TO BIPHASIC INSULIN ASPART 30 IN PEOPLE WITH TYPE-2 DIABETES

被引：0
|
作者：
Home, P. D. [1 ]
Soewondo, P. [2 ]
Hussein, Z. [3 ]
Shafie, A. A. [4 ]
AlRaddady, K. [5 ]
Baadbad, R. [6 ]
Hammerby, E. [7 ]
Nikolajsen, A. [7 ]
Andersen, M. F. B. [8 ]
Henriksen, O. [8 ]
机构：
[1] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Indonesia, Jakarta, Indonesia
[3] Hosp Putrajaya, Putrajaya, Malaysia
[4] Univ Sains Malaysia, George Town, Malaysia
[5] King Saud Med City, Riyadh, Saudi Arabia
[6] KSMC, Pharmacoecon Ctr, Riyadh, Saudi Arabia
[7] Novo Nordisk AS, Soborg, Denmark
[8] Last Mile PS, Copenhagen K, Denmark
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A164 / A164
页数：1
相关论文
共 50 条
  • [1] SHORT AND LONG-TERM COST-EFFECTIVENESS OF STARTING BIPHASIC INSULIN ASPART 30 IN INSULIN-NAIVE PEOPLE WITH TYPE-2 DIABETES
    Home, P. D.
    Soewondo, P.
    Hussein, Z.
    Shafie, A. A.
    AlRaddady, K.
    Baadbad, R.
    Hammerby, E.
    Nikolajsen, A.
    Andersen, M. F. B.
    Henriksen, O.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A164 - A164
  • [2] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Nikolajsen, Annie
    Shafie, Asrul Akmal
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
  • [3] COST-EFFECTIVENESS OF SWITCHING TO BIPHASIC INSULIN ASPART FROM HUMAN PREMIX INSULIN IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xiao, J.
    Bian, X.
    Zhang, Y.
    Yang, L.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A250 - A250
  • [4] PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
    Aagren, M.
    Thomsen, T. L.
    Knudsen, V. K.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A10 - A10
  • [5] Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes
    Valentine, William J.
    Pollock, Richard F.
    Plun-Favreau, Juliette
    White, Jeremy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1399 - 1412
  • [6] An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes
    Shafie, Asrul Akmal
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Home, Philip
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (02) : 319 - 327
  • [7] COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
    Suchankova, E.
    Dolezal, T.
    Pisarikova, Z.
    Rychna, K.
    Bartaskova, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A405 - A406
  • [8] Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea
    Lee, Kyoung Hee
    Seo, Se Jin
    Smith-Palmer, Jayne
    Palmer, James L.
    White, Jeremy
    Valentine, William J.
    [J]. VALUE IN HEALTH, 2009, 12 : S55 - S61
  • [9] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
    Lynch, M.
    Scheijbeler, H.
    Kotchie, R.
    Neilsen, S.
    White, J.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
  • [10] Cost-effectiveness of Biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting
    Aristides, M.
    Kotchie, R.
    Nielsen, C.
    Valentine, W. J.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
12345